High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer (Q86214764)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

title

High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

7

Wilko Weichert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

author name string

Nicole Pfarr

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Albrecht Stenzinger

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Roland Penzel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Arne Warth

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Hendrik Dienemann

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Peter Schirmacher

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

Volker Endris

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

publication date

23 September 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

Genes, Chromosomes and Cancer

24 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

page(s)

30-44

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

ROS1 rearrangements define a unique molecular class of lung cancers

24 February 2020

cites work

1 reference

7 January 2021

Lessons learned from lung cancer genomics: the emerging concept of individualized diagnostics and treatment

1 reference

7 January 2021

Correlations between the percentage of tumor cells showing an anaplastic lymphoma kinase (ALK) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cance

1 reference

7 January 2021

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

1 reference

7 January 2021

Immunohistochemistry is a reliable screening tool for identification of ALK rearrangement in non-small-cell lung carcinoma and is antibody dependent

1 reference

7 January 2021

Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)

1 reference

7 January 2021

Immunohistochemistry, fluorescence in situ hybridization, and reverse transcription-polymerase chain reaction for the detection of anaplastic lymphoma kinase gene rearrangements in patients with non-small cell lung cancer: potential advantages and m

1 reference

7 January 2021

Molecular diagnostic profiling of lung cancer specimens with a semiconductor-based massive parallel sequencing approach: feasibility, costs, and performance compared with conventional sequencing

1 reference

7 January 2021

COSMIC: exploring the world's knowledge of somatic mutations in human cancer

1 reference

7 January 2021

EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset.

1 reference

7 January 2021

Distinctive Spatiotemporal Stability of Somatic Mutations in Metastasized Microsatellite-stable Colorectal Cancer

1 reference

7 January 2021

A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing.

1 reference

7 January 2021

The combinatorial complexity of cancer precision medicine

1 reference

7 January 2021

KIF5B-RET fusions in lung adenocarcinoma.

1 reference

7 January 2021

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

1 reference

7 January 2021

ClinVar: public archive of relationships among sequence variation and human phenotype

1 reference

7 January 2021

Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors

1 reference

7 January 2021

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies

1 reference

7 January 2021

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

1 reference

7 January 2021

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

1 reference

7 January 2021

Sensitive and specific detection of EML4-ALK rearrangements in non-small cell lung cancer (NSCLC) specimens by multiplex amplicon RNA massive parallel sequencing

1 reference

7 January 2021

Fluorescence in situ hybridization, immunohistochemistry, and next-generation sequencing for detection of EML4-ALK rearrangement in lung cancer

1 reference

7 January 2021

Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer.

1 reference

7 January 2021

TaqMan based real time PCR assay targeting EML4-ALK fusion transcripts in NSCLC.

1 reference

7 January 2021

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

1 reference

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

7 January 2021

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

1 reference

7 January 2021

dbSNP: the NCBI database of genetic variation

1 reference

7 January 2021

Cancer statistics, 2014

1 reference

7 January 2021

Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer

1 reference

7 January 2021

Quantitative analysis of diagnostic guidelines for HER2-status assessment

1 reference

7 January 2021

Semiconductor-based sequencing of formalin-fixed, paraffin-embedded colorectal cancer samples

1 reference

7 January 2021

A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK.

1 reference

7 January 2021

Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.

1 reference

7 January 2021

RET, ROS1 and ALK fusions in lung cancer

1 reference

7 January 2021

Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification

1 reference

7 January 2021

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): results of a multi-centre ALK-testing

1 reference

7 January 2021

Multicenter immunohistochemical ALK-testing of non-small-cell lung cancer shows high concordance after harmonization of techniques and interpretation criteria

1 reference

7 January 2021

ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases

1 reference

7 January 2021

EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype.

1 reference

7 January 2021

A mass spectrometry assay to simultaneously analyze ROS1 and RET fusion gene expression in non-small-cell lung cancer

1 reference

7 January 2021

Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.

1 reference

7 January 2021

Lung cancers with concomitant EGFR mutations and ALK rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation.

1 reference

7 January 2021

Anchored multiplex PCR for targeted next-generation sequencing

1 reference

7 January 2021

Identifiers

DOI

10.1002/GCC.22297

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26394895%20AND%20SRC:MED&resulttype=core&format=json

24 February 2020

1 reference